$AGMB News

Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

AgomAb Therapeutics H1 EPS $(0.93)

B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34

Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?

Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib

HC Wainwright & Co. Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $35

AgomAb Therapeutics: High Risk, High Reward Stock

Agomab to Participate in Upcoming Conferences

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Secures US Patent For AGMB-447, Investigational Inhaled Lung-Restricted Small Molecule Inhibitor Of ALK5 For Idiopathic Pulmonary Fibrosis Treatment

Leerink Partners Initiates Coverage On AgomAb Therapeutics with Outperform Rating, Announces Price Target of $36

JP Morgan Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $32

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday